Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloRelapseMMStudy
2021-001005-67Phase 3Active
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daratumumab, carfilzomib, ixazomib, elotuzumab, pomalidomide and 3 more in multiple myeloma (MM) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Overall survival at 5 years. Started Sep 2021; status: active.
02
Drugs
daratumumabcarfilzomibixazomibelotuzumabpomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2021-001005-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001005-67.